fda semaglutide obesity A big win for Wegovy: Weight loss drug first in history to gain approval for reducing heart risks Oral Obesity Drugs Edge Closer

Brand note: Ozempic is a trademark of Novo Nordisk A/S, not affiliated with Omzo

Strategies for Long-Term Weight Maintenance In the biggest study on discontinuing semaglutide, two-thirds of people regained all the weight within one year

In pregnancy, choline deficiency increases the risk of neural tube defects and affects brain development in the baby.[ref] What do the different types of choline do in the body

36 Months: Long-Term Changes With continued use, users may see more meaningful changes in body weight and eating habits

In February 2026, full results from the REDEFINE 2 study showed CagriSema achieving 23% weight loss at 84 weeks but falling short of its primary endpoint under the treatment policy estimand (which measures efficacy across all patients regardless of whether they completed treatment, rather than only those who remained on it)